Overview
- Net sales fell 3.8% to $114.6 million but topped Wall Street estimates, with GAAP earnings of $0.02 per share exceeding consensus.
- The company reiterated full-year guidance, with commentary indicating revenue around $420.5 million at the midpoint.
- Channel performance diverged: specialty retail declined 13.5% to $36.9 million, professional rose 5.3% to $44.5 million, and direct-to-consumer slipped 2.9% to $33.3 million.
- Regional mix shifted as U.S. sales dropped 14.6% while international grew 7.1%, supported by a pro-first push with stylist education and new masks.
- Olaplex announced its first acquisition, Boston-based Purvala Bioscience, to deepen in-house science capabilities; shares jumped intraday before easing, reflecting ongoing volatility.